Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -98.48% | 1.24% | 467.37% | -51.53% | 3,037.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -98.20% | 1.55% | 57.42% | -21.58% | 2,667.97% |
| Operating Income | 98.20% | -1.55% | -57.42% | 21.58% | -2,667.97% |
| Income Before Tax | 97.69% | 1.47% | 2.02% | 83.73% | -1,504.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 97.69% | 1.47% | 2.02% | 83.73% | -1,504.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.69% | 1.47% | 2.02% | 83.73% | -1,504.49% |
| EBIT | 98.20% | -1.55% | -57.42% | 21.58% | -2,667.97% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 98.57% | 75.00% | 66.67% | 98.04% | -262.79% |
| Normalized Basic EPS | 97.73% | 80.00% | 100.00% | 96.88% | -109.52% |
| EPS Diluted | 98.57% | 75.00% | 33.33% | 98.04% | -488.89% |
| Normalized Diluted EPS | 97.73% | 80.00% | 100.00% | 96.88% | -450.00% |
| Average Basic Shares Outstanding | 31.14% | 328.83% | 326.19% | 506.98% | 754.06% |
| Average Diluted Shares Outstanding | 31.14% | 328.83% | 326.19% | 506.98% | 246.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
